
15.



on the cancer cell, the antibody being produced by a hybridoma selected from the group of hybridomas having ATCC accession number PTA-717, PTA-718, PTA-719, PTA-720, PTA-880, or PTA-2265.

- 18 (Amended) The antibody of claim 19 which is produced in bacteria.
- 19. (Amended) An anti-PSCA monoclonal antibody that inhibits the growth of PSCA-expressing cancer cells in vivo, wherein the antibody internalizes upon binding to PSCA on the cancer cell, and wherein the antibody is a humanized form of an anti-PSCA antibody produced by a hybridoma selected from the group of hybridomas having ATCC accession number PTA-717, PTA-718, PTA-719, PTA-720, PTA-880, or PTA-2265.
- 20. (Amended) The antibody of claim 15 or claim 19, wherein the cancer cells are from a cancer selected from the group consisting of prostate cancer, bladder cancer and lung cancer.
- (Amended) A composition comprising the antibody of claim 15 or claim 19, and 29. a carrier.
- (Amended) The composition of claim 29, wherein the carrier is a pharmaceutical 32. carrier.